Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 12:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Agranulocytosis Clear all
Completed Phase 3 Interventional

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

NCT00003739
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jun 10, 2026, 12:42 PM EDT
Recruiting Phase 3 Interventional

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297
View directory record Official record
Conditions
Neutropenia
Interventions
Mavorixafor, Placebo
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 12:42 PM EDT
Completed No phase listed Observational

Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

NCT03262584
View directory record Official record
Conditions
Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 2 Interventional

Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia

NCT00909584
View directory record Official record
Conditions
Severe Chronic Neutropenia
Interventions
Ezatiostat Hydrochloride
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jun 10, 2026, 12:42 PM EDT
Not yet recruiting Phase 4 Interventional

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

NCT07571135
View directory record Official record
Conditions
CMV Infection, CMV, CMV Viremia, CMV Disease
Interventions
Letermovir, Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
Elisabeth Kincaide
Government
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 1 Interventional Results available

AMD 3100 for Treatment of Myelokathexis

NCT01058993
View directory record Official record
Conditions
Neutropenia
Interventions
AMD3100 or plerixafor
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 1 Interventional

Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC

NCT00000711
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Zidovudine, Sargramostim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT01619423
View directory record Official record
Conditions
Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions
PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl)
Drug
Lead sponsor
Egetis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

NCT02953340
View directory record Official record
Conditions
Neutropenia, Breast Cancer
Interventions
SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
49
States / cities
Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

NCT04526886
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer, Small Bowel Cancer, Appendix Cancer
Interventions
Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

Extended Dosing With Eltrombopag for Severe Aplastic Anemia

NCT01891994
View directory record Official record
Conditions
Severe Aplastic Anemia (SAA)
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jun 10, 2026, 12:42 PM EDT
Completed No phase listed Observational

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

NCT04710212
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
Interventions
No intervention.
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
San Francisco, California • Nutley, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 4 Interventional

Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin

NCT00194857
View directory record Official record
Conditions
Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
Interventions
erythropoietin, GCSF
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jun 10, 2026, 12:42 PM EDT
Recruiting Phase 4 Interventional

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NCT05626530
View directory record Official record
Conditions
Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
Interventions
Letermovir
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)

NCT02766647
View directory record Official record
Conditions
Neutropenia (Low White Blood Cell Count)
Interventions
Filgrastim Hospira (US), US-approved Neupogen®
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Jun 10, 2026, 12:42 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

NCT02190721
View directory record Official record
Conditions
Neutropenia
Interventions
tbo-filgrastim
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Jackson, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

Eltrombopag for Moderate Aplastic Anemia

NCT01328587
View directory record Official record
Conditions
Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia

NCT00497809
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
AVI-014 versus Filgrastim
Drug
Lead sponsor
AviGenics
Industry
Eligibility
18 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Anaheim, California • Greenbrae, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 2 Interventional

Outpatient Neutropenic Diet Study

NCT00947648
View directory record Official record
Conditions
Leukemia, Neutropenia
Interventions
Raw Fruits & Vegetables, Cooked Foods
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 1 Interventional

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

NCT00352300
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Adjuvant Therapy, Carboplatin, Paclitaxel, Pegfilgrastim
Procedure · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 1Phase 2 Interventional

Anidulafungin in Treating Immunocompromised Children With Neutropenia

NCT00068471
View directory record Official record
Conditions
Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anidulafungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jun 10, 2026, 12:42 PM EDT